<code id='830B39992B'></code><style id='830B39992B'></style>
    • <acronym id='830B39992B'></acronym>
      <center id='830B39992B'><center id='830B39992B'><tfoot id='830B39992B'></tfoot></center><abbr id='830B39992B'><dir id='830B39992B'><tfoot id='830B39992B'></tfoot><noframes id='830B39992B'>

    • <optgroup id='830B39992B'><strike id='830B39992B'><sup id='830B39992B'></sup></strike><code id='830B39992B'></code></optgroup>
        1. <b id='830B39992B'><label id='830B39992B'><select id='830B39992B'><dt id='830B39992B'><span id='830B39992B'></span></dt></select></label></b><u id='830B39992B'></u>
          <i id='830B39992B'><strike id='830B39992B'><tt id='830B39992B'><pre id='830B39992B'></pre></tt></strike></i>

          fashion

          fashion

          author:leisure time    Page View:5
          Tome cofounders Jonathan Gootenberg, left, and Omar Abudayyeh, a scientific team that's trying to reinvent gene editing for a new era of biotech innovation.
          Suzanne Kreiter/Globe staff

          WATERTOWN — Their brainstorming began in an MIT class in 2010 when the eager undergrads shot each other emails about how to solve a bioengineering equation. It has continued for 14 years over sushi dinners, between Marvel movies, and during rowing-machine workouts.

          Together, Omar Abudayyeh, 33, and Jonathan Gootenberg, 32, have probed the mysteries of genomic editing and COVID detection. They co-published 10 scientific papers, helped launch two medical-diagnostic companies, and cofounded a Watertown startup, Tome Biosciences, that reengineers genes and cells to cure diseases. They also run the Abudayyeh-Gootenberg Lab at Harvard.

          advertisement

          Gootenberg and Abudayyeh are an unusual pair, two scientists — a Jewish American and a Palestinian American — who prefer working together in a field that often draws solitary researchers and rewards individual achievement.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          leisure time

          Bright Health sells Medicare Advantage business to Molina
          Bright Health sells Medicare Advantage business to Molina

          BrightHealthisofficiallyleavingthehealthinsurancemarket.ThecompanyhasagreedtosellitsMedicareAdvantag

          read more
          FDA reviewers ask if approval of Lilly’s Alzheimer’s drug should be restricted
          FDA reviewers ask if approval of Lilly’s Alzheimer’s drug should be restricted

          DarronCummings/APScientistsattheFoodandDrugAdministrationhavetwobigquestionsaboutEliLilly’sexperimen

          read more
          23andMe had bad news about my health. I wish a person had delivered it
          23andMe had bad news about my health. I wish a person had delivered it

          ERICBARADAT/AFP/GettyImagesLastsummer,IthoughtitmightbefuntohavemyDNAanalyzed.Twocompanies,23andMean

          read more

          'Essentially witchcraft:' A former naturopath takes on the field

          ErosDervishiforSTATBrittHermesonceconsideredherselfadoctor.Now,she’sanapostate.Hermesspentthreeyears